Valeo Financial Advisors’s Intellia Therapeutics NTLA Stock Holding History

Valeo Financial Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,082	Closed	-$328K	–	1359
2021 Q1	$328K	Sell	4,082 -5,000	-55%	-$336K	0.02%	340
2020 Q4	$494K	Hold	9,082	–	–	0.03%	249
2020 Q3	$181K	Hold	9,082	–	–	0.02%	348
2020 Q2	$191K	Buy	9,082 +8,311	+1,078%	+$141K	0.02%	330
2020 Q1	$10K	Hold	771	–	–	﹤0.01%	1103
2019 Q4	$11K	Hold	771	–	–	﹤0.01%	1091
2019 Q3	$10K	Hold	771	–	–	﹤0.01%	1029
2019 Q2	$13K	Hold	771	–	–	﹤0.01%	964
2019 Q1	$13K	Buy	771 +609	+376%	+$9.08K	﹤0.01%	900
2018 Q4	$2K	Hold	162	–	–	﹤0.01%	1299
2018 Q3	$3K	Buy	162 +82	+103%	+$2.39K	﹤0.01%	1366
2018 Q2	$2K	Hold	80	–	–	﹤0.01%	1362
2018 Q1	$2K	Hold	80	–	–	﹤0.01%	1340
2017 Q4	$2K	Hold	80	–	–	﹤0.01%	1193
2017 Q3	$2K	Buy	+80	New	+$1.51K	﹤0.01%	1032

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Valeo Financial Advisors's NTLA Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2021, closing a stake of 4,082 shares — an estimated $328K sold.

Valeo Financial Advisors first reported a position in NTLA in Q3 2017 and held it in 15 quarters. The position peaked at $494K in Q4 2020. 335 funds tracked by Wall St. Rank hold NTLA as of Q2 2021.

Valeo Financial Advisors reported no remaining Intellia Therapeutics position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 4,082 Intellia Therapeutics shares in Q2 2021, an estimated $328K.
Valeo Financial Advisors first reported a position in Intellia Therapeutics in Q3 2017 and held it in 15 quarters.
Valeo Financial Advisors's Intellia Therapeutics position peaked at $494K in Q4 2020.
335 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.